NCT07612046 A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
| NCT ID | NCT07612046 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 79 participants |
| Start Date | 2026-05-20 |
| Primary Completion | 2028-05-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 79 participants in total. It began in 2026-05-20 with a primary completion date of 2028-05-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: * Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual * Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer * Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2 * Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+ For this pilot MRP study, we will additionally apply the following Criteria: * Consents to follow-up contact * US residents * Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass) * No metallic artifacts covering the pancreas on prior MRCP * Scheduled for endoscopic ultrasound * No new contraindications for MRI (e.g. new MR unsafe device) * No history of claustrophobia or use of anxiolytic on prior MRI * No history of abdominal surgery that may affect interpretation of either EUS or MR * No medical conditions that confers increased and/or unacceptable risk for anesthesia We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget. * Documentation of Disease o No pathologic confirmation of disease is necessary * Definition of Disease N/A * Not Pregnant and Not Nursing * Required Organ Function N/A Exclusion Criteria: \-
Contact & Investigator
Richard Kinh Gian Do, MD, PhD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07612046 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07612046 currently recruiting?
Yes, NCT07612046 is actively recruiting participants. Contact the research team at dok@mskcc.org for enrollment information.
Where is the NCT07612046 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT07612046 clinical trial?
NCT07612046 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Richard Kinh Gian Do, MD, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 79 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.